​

Aytu BioPharma (AYTU) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AYTU Stock Rating

Aytu BioPharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

AYTU Price Target Upside V Benchmarks

TypeNameUpside
StockAytu BioPharma-
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.58%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.31$2.31$2.31
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2612---3
Aug, 2612---3
Jul, 2612---3
Jun, 2612---3
May, 2612---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 22, 2026CitigroupPositivePositivehold

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$-74.01$-5.11$-2.86$-2.16$-1.16-
Avg Forecast$-66.60$-6.16$-2.49$0.60$0.55$1.46
High Forecast$-66.60$-6.16$-2.49$0.60$0.55$1.46
Low Forecast$-66.60$-6.16$-2.49$0.60$0.55$1.46
Surprise %11.13%-17.05%14.86%-460.00%-310.91%-

Revenue Forecast

$55M $66M $77M $88M $99M $110M Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$96.67M$107.40M$65.18M$66.38M$57.57M-
Avg Forecast$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
High Forecast$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
Low Forecast$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
Surprise %1.86%2.91%-19.85%-5.64%-17.29%-

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$-108.78M$-17.05M$-15.84M$-13.56M$-14.25M-
Avg Forecast$-368.96M$-34.11M$-7.28M$3.32M$3.05M$8.09M
High Forecast$-368.96M$-34.11M$-5.82M$3.32M$3.05M$8.09M
Low Forecast$-368.96M$-34.11M$-8.73M$3.32M$3.05M$8.09M
Surprise %-70.52%-50.02%117.70%-508.15%-567.91%-

AYTU Forecast FAQ

Is Aytu BioPharma stock a buy?

Aytu BioPharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aytu BioPharma is a favorable investment for most analysts.

What is Aytu BioPharma's price target?

Aytu BioPharma's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.31.

How does Aytu BioPharma stock forecast compare to its benchmarks?

Aytu BioPharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (26.58%).

What is the breakdown of analyst ratings for Aytu BioPharma over the past three months?

  • September 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aytu BioPharma’s EPS forecast?

Aytu BioPharma's average annual EPS forecast for its fiscal year ending in June 2027 is $1.46, marking a -225.86% decrease from the reported $-1.16 in 2026..

What is Aytu BioPharma’s revenue forecast?

Aytu BioPharma's average annual revenue forecast for its fiscal year ending in June 2027 is $69.33M, reflecting a 20.43% increase from the reported $57.57M in 2026.

What is Aytu BioPharma’s net income forecast?

Aytu BioPharma's net income forecast for the fiscal year ending in June 2027 stands at $8.09M, representing a -156.73% decrease from the reported $-14.252M in 2026.